Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.35 |
| ▸ | PDIA6 | Q15084 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21718395 | 0.86 | PDK2 (0.40) | SMN1; SMN2LTA4HPDK2MAOB | |
| SCHEMBL21718946 | 0.85 | BRD4 (0.40) | KIF11FGFR1 | |
| SCHEMBL22809630 | 0.84 | SLC7A5 (0.48) | SMN1; SMN2TAAR1LTA4HPLA2G2AKIF11 | |
| Hydrochloric Acid SCHEMBL20595234 | 0.83 | SLC7A5 (0.47) | SMN1; SMN2TAAR1LTA4HPLA2G2AKIF11 | |
| Hydrochloric Acid SCHEMBL30450550 | 0.83 | SLC7A5 (0.47) | SMN1; SMN2TAAR1LTA4HPLA2G2AKIF11 | |
| SCHEMBL18120375 | 0.82 | NQO1 (0.46) | LTA4HKIF11PDK2ESR2 | |
| SCHEMBL19532869 | 0.82 | KIF11 (0.36) | KIF11MAOBAOC3SLC7A5 | |
| SCHEMBL18294055 | 0.82 | HTR1B (0.46) | SMN1; SMN2PDK2 | |
| SCHEMBL16473860 | 0.81 | PDK2 (0.41) | KIF11PDK2MAOB | |
| SCHEMBL11834693 | 0.81 | KIF11 (0.35) | KIF11MAOBAOC3SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822115-B2 | Nitrogen containing compounds and their use as antibacterial agents | WOCKHARDT LIMITED (IN) | 2017-11-21 | — | — | US | disclosed |
| US-20160355516-A1 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | WOCKHARDT LIMITED (IN) | 2016-12-08 | — | — | US | disclosed |
| WO-2012045729-A1 | IMIDAZO [1, 2 -A] PYRIDINE AND PYRAZOLO [1, 5 -A] PYRIDINE DERIVATIVES AS TRPV1 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355516-A1 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | NOS2, NOS1, NCF1 | SMN1; SMN2 2575/4885TAAR1 2947/4885LTA4H 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.